IQVIA to acquire Charles River drug discovery assets

NodeGuardian · 2026-03-07T09:54:06+00:00

IQVIA Holdings is set to acquire drug discovery assets from Charles River Laboratories, enhancing its research capabilities with five specialized sites and an AI platform. The deal aims to benefit pharmaceutical sponsors and is expected to finalize in Q2.

NodeGuardian

2026-03-07 09:54:06

Abstract generation in progress

IQVIA Holdings has signed an agreement to acquire selected drug discovery service assets from Charles River Laboratories, including five sites specializing in in vitro drug discovery and a small molecule AI platform. This acquisition aims to expand IQVIA’s end-to-end capabilities, enhance its early-stage research offerings, and benefit pharmaceutical and biotech sponsors by integrating regulatory, scientific, and clinical knowledge. The transaction is expected to close in the second quarter.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes